{"id":53190,"date":"2023-01-23T17:02:46","date_gmt":"2023-01-23T16:02:46","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/tevogen-bio-announces-positive-proof-of-concept-clinical-trial-results-of-its-off-the-shelf-allogeneic-cytotoxic-cd8-t-cell-therapy-for-treatment-of-acute-high-risk-covid-patients-first-clinical-pr\/"},"modified":"2023-01-23T17:02:46","modified_gmt":"2023-01-23T16:02:46","slug":"tevogen-bio-announces-positive-proof-of-concept-clinical-trial-results-of-its-off-the-shelf-allogeneic-cytotoxic-cd8-t-cell-therapy-for-treatment-of-acute-high-risk-covid-patients-first-clinical-pr","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/tevogen-bio-announces-positive-proof-of-concept-clinical-trial-results-of-its-off-the-shelf-allogeneic-cytotoxic-cd8-t-cell-therapy-for-treatment-of-acute-high-risk-covid-patients-first-clinical-pr\/","title":{"rendered":"Tevogen Bio Announces Positive Proof-of-Concept Clinical Trial Results of Its Off-The-Shelf, Allogeneic Cytotoxic CD8+ T Cell Therapy for Treatment of Acute High-Risk COVID Patients, First Clinical Product of Company\u2019s Precision Cell Therapy Platform"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\nThe primary study endpoints were related to safety. No dose-limiting toxicities or significant adverse events related to TVGN 489, including Cytokine Release Syndrome, were observed in any patient at any dose level.\n<\/li>\n<li>\nSecondary endpoints measuring the reduction of viral load and the presence of cellular and humoral anti-COVID-19 responses after treatment were met.\n<\/li>\n<li>\nFifty percent (50%) of treatment arm patients were immunocompromised versus six percent (6%) of observational arm patients.\n<\/li>\n<li>\nTreatment arm patients were infected by a variety of COVID variants ranging from Delta through Omicron BA.5.2.\n<\/li>\n<li>\nObservational arm patients were treated with standard of care including monoclonal antibodies.\n<\/li>\n<li>\nKey observational findings: All treatment arm patients returned to their baseline level of health within 14 days of treatment. No incidence of COVID reinfection or Long COVID was observed in any treated patient at the time of the six (6) month follow up.\n<\/li>\n<\/ul>\n<p>WARREN, N.J.&#8211;(BUSINESS WIRE)&#8211;<a href=\"https:\/\/twitter.com\/hashtag\/COVID19?src=hash\" target=\"_blank\" rel=\"noopener\">#COVID19<\/a>&#8212;<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.tevogen.com&amp;esheet=53289167&amp;newsitemid=20230123005565&amp;lan=en-US&amp;anchor=Tevogen+Bio&amp;index=1&amp;md5=326586b1680e5dd04fb9f5bf02166e32\" rel=\"nofollow noopener\" shape=\"rect\">Tevogen Bio<\/a> today announced positive topline results from its Proof-of-Concept (POC) <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2Fstudy%2FNCT04765449&amp;esheet=53289167&amp;newsitemid=20230123005565&amp;lan=en-US&amp;anchor=clinical+trial&amp;index=2&amp;md5=5102b52e67901193d3cc2dc4bec89269\" rel=\"nofollow noopener\" shape=\"rect\">clinical trial<\/a> designed to evaluate the safety and feasibility of TVGN 489, the company\u2019s first clinical product of its precision T Cell therapy platform, for the treatment of acute high-risk COVID-19 patients. TVGN 489 is a genetically unmodified, off-the-shelf, allogeneic cytotoxic CD8+ T lymphocyte (CTL) product with precise targets across the SARS-CoV-2 genome, not just the Spike protein. To date, TVGN 489 targets, identified early in the pandemic, persist in the most recent SARS-CoV-2 variants. The open label comparative trial was conducted at <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.jeffersonhealth.org%2Flocations%2Fthomas-jefferson-university-hospital&amp;esheet=53289167&amp;newsitemid=20230123005565&amp;lan=en-US&amp;anchor=Thomas+Jefferson+University+Hospital&amp;index=3&amp;md5=63ee603443e549e041cffc157eae44fc\" rel=\"nofollow noopener\" shape=\"rect\">Thomas Jefferson University Hospital<\/a> in Philadelphia to assess the safety and feasibility of TVGN 489 when given at one of four escalating doses. Twelve ambulatory patients with newly diagnosed COVID-19 infection who were at higher risk for infection-related complications due to advanced age or CDC-defined comorbid conditions such as heart, lung, liver, and kidney disease, hypertension, diabetes, cancer, or obesity were treated on the trial. Eighteen patients, who also met these criteria but did not receive TVGN 489 because of lack of HLA matching, were enrolled on an observational arm in the study and treated with standard of care including monoclonal antibodies.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20230123005565\/en\/1073275\/5\/Tevogen_Logo_800px.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230123005565\/en\/1073275\/21\/Tevogen_Logo_800px.jpg\"><\/a><\/p>\n<p>\nThe treated patients had between 2 to 5 comorbidities each and 6 out of 12 (50%) were immunocompromised due to treatment for cancer or autoimmune disease. Multiple COVID-19 variants were detected in the group. Safety endpoints included infusion reactions, grade 4 adverse events, GVHD, marrow aplasia, neurotoxicity and CRS.\n<\/p>\n<p>\n<i>Table 1. Treatment arm (n=12)<\/i>\n<\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl\">\n<tr>\n<td class=\"bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Safety Criteria as Defined in the Study Protocol<\/b>\n<\/p>\n<\/td>\n<td class=\"bwtopsingle bwsinglebottom bwrightsingle bwalignc bwvertalignm bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n<b>Trial Result<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nInfusion Reactions (\u2265 Grade 3)\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwalignc bwvertalignm\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n0\/12\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nCytokine release syndrome, (Grade \u2265 2)\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwalignc bwvertalignm\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n0\/12\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nNeurotoxicity (Grade \u2265 2)\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwalignc bwvertalignm\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n0\/12\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nGraft versus Host Disease\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwalignc bwvertalignm\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n0\/12\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nGrade \u22654 Adverse Events\n<\/p>\n<p class=\"bwcellpmargin\">\n(Related to the CTL therapy &amp; outside the spectrum of identified COVID related adverse events)\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwalignc bwvertalignm\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n0\/12\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\nSafety endpoints were reviewed after each dose level and confirmed by an independent Data and Safety Monitoring Committee at Jefferson and by both internal and external Medical Monitors who provided permission to escalate to the next dose level. Based on the data in Table 1, safety was confirmed with the minimum required number of patients per dosing level. In addition to safety endpoints, secondary endpoints measuring the reduction of viral load and the presence of cellular and humoral anti-COVID-19 responses after treatment were also met.\n<\/p>\n<p>\nEnrollment was completed in nine months, and six-month follow-up for all patients concluded on January 19, 2023. In the treatment arm, no patient experienced progression of their COVID-19 infection and all patients returned to their baseline level of health within 14 days of treatment. There were no incidences of COVID-19 reinfection or Long COVID observed in any treated patient through the 6-month follow-up period. While patients in the treatment group experienced COVID-19 symptom relief in a rapid, consistent timeframe as self-reported and confirmed by the investigators, patients on the observation arm showed improvement in a less consistent, and in some cases, longer time frame.\n<\/p>\n<p>\nThe study investigators plan to submit the full data for publication in a peer-reviewed journal in the upcoming weeks.\n<\/p>\n<p>\n\u201cThe highly encouraging data of TVGN 489 allows us to turn our attention to the critical unmet need in the COVID-19 landscape. Immunocompromised and the elderly and infirm usually do not benefit from currently available prevention or treatment strategies for COVID-19 and remain highly vulnerable to poor outcomes with a COVID-19 infection. These patients, as well as those individuals with Long COVID, urgently require new treatment options,\u201d said <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fin%2Fdolores-grosso-a7848331%2F&amp;esheet=53289167&amp;newsitemid=20230123005565&amp;lan=en-US&amp;anchor=Dr.+Dolores+Grosso%2C+DNP&amp;index=4&amp;md5=16afeea20ca7e1db778221211782e2f2\" rel=\"nofollow noopener\" shape=\"rect\">Dr. Dolores Grosso, DNP<\/a>, the Principal Investigator of the trial.\n<\/p>\n<p>\n\u201cI\u2019m greatly encouraged by the POC trial experience of TVGN 489 and hopeful that our investigational COVID-19 therapy will eventually offer hope to a substantial segment of patients,\u201d said <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fin%2Fneal-flomenberg-213a74126%2F&amp;esheet=53289167&amp;newsitemid=20230123005565&amp;lan=en-US&amp;anchor=Dr.+Neal+Flomenberg%2C+MD&amp;index=5&amp;md5=db42c9438c2d7ec3b2fb28db7fe38d05\" rel=\"nofollow noopener\" shape=\"rect\">Dr. Neal Flomenberg, MD<\/a>, Tevogen\u2019s Chief Scientific Officer.\n<\/p>\n<p>\n\u201cTevogen\u2019s goal is to provide access to the vast and unprecedented potential of personalized immunotherapies for large patient populations impacted by common cancers and viral infections. The ability to administer TVGN 489 in the outpatient setting and the ongoing work by Tevogen scientists to use this product in diverse patient populations, highlights Tevogen Bio\u2019s commitment to patient accessibility,\u201d said Tevogen founder and CEO <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fin%2Fryansaadi%2F&amp;esheet=53289167&amp;newsitemid=20230123005565&amp;lan=en-US&amp;anchor=Dr.+Ryan+Saadi%2C+MD%2C+MPH&amp;index=6&amp;md5=faa4417d3a35f9d16a62149c0ccfbae7\" rel=\"nofollow noopener\" shape=\"rect\">Dr. Ryan Saadi, MD, MPH<\/a>.\n<\/p>\n<p>\nTevogen\u2019s research pipeline includes treatment for other serious viral infections and cancers using their precision T Cell platform.\n<\/p>\n<p>\n<b>About Tevogen\u2019s Next Generation Precision T Cell Platform<\/b>\n<\/p>\n<p>\nTevogen\u2019s next generation precision <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftevogen.com%2Ftechnology%2F&amp;esheet=53289167&amp;newsitemid=20230123005565&amp;lan=en-US&amp;anchor=T-cell+platform&amp;index=7&amp;md5=4e57a5674b8b208085c06cba68c88886\" rel=\"nofollow noopener\" shape=\"rect\">T-cell platform<\/a> is designed to provide increased immunologic specificity to eliminate malignant and virally infected cells, while allowing healthy cells to remain intact. Multiple, precise candidate targets on viral or malignant cells are selected in advance for T cell sensitization and effector functions with the goal of overcoming the mutational escape capacity of cancer cells and viruses while limiting cross-reactivity.\n<\/p>\n<p>\nTevogen is investigating its technology\u2019s potential to overcome the primary barriers to the broad application of personalized T cell therapies: potency, purity, production-at-scale, and patient-pairing, without the limitations of current approaches. Tevogen\u2019s goal is to provide access to the vast and unprecedented potential of developing personalized immunotherapies for large patient populations impacted by common cancers and viral infections. The ability to administer TVGN-489 in the outpatient setting and the ongoing work by Tevogen scientists to use this product in diverse patient populations, highlights Tevogen Bio\u2019s commitment to patient accessibility.\n<\/p>\n<p>\n<b>About Tevogen Bio<\/b>\n<\/p>\n<p>\nTevogen Bio is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen\u2019s leadership believes that accessible personalized immunotherapies are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation in the post-pandemic world.\n<\/p>\n<p>\n<b>Forward Looking Statements<\/b>\n<\/p>\n<p>\nThis press release contains certain forward-looking statements relating to Tevogen Bio\u2122 Inc (the \u201cCompany\u201d) and its business. These statements are based on management\u2019s current expectations and beliefs as of the date of this release and are subject to several factors which involve known and unknown risks, delays, uncertainties, and other factors not under the Company\u2019s control that may cause actual results, performance or achievements to be materially different from the results, performance or other expectations implied by these forward-looking statements. Forward-looking statements can sometimes be identified by terminology such as \u201cmay,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cintend,\u201d \u201cexpect,\u201d \u201cbelieve,\u201d \u201cpotential,\u201d and \u201cpossible,\u201d or their negatives or comparable terminology, as well as other words and expressions referencing future events, conditions, or circumstances. In any forward-looking statement in which the Company expresses an expectation or belief as to future results, there can be no assurance that the statement or expectation or belief will be achieved. Various factors may cause differences between the Company\u2019s expectations and actual results, including, among others: the Company\u2019s limited operating history; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, and approval and commercial development; risks associated with intellectual property protection; and risks related to matters that could affect the Company\u2019s future financial results, including the commercial potential, sales, and pricing of the Company\u2019s products. Except as required by law, the Company undertakes no obligation to update the forward-looking statements or any of the information in this release, or provide additional information, and expressly disclaims any and all liability and makes no representations or warranties in connection herewith or with respect to any omissions therefrom.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nTevogen Communications<br \/>\n<br \/>T: 1 877 TEVOGEN, Ext 701<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;&#x69;&#108;&#x74;&#x6f;:&#x43;&#x6f;m&#109;&#x75;n&#105;&#x63;a&#116;&#x69;o&#110;&#x73;&#64;&#84;&#x65;&#x76;&#111;&#x67;&#x65;&#110;&#x2e;&#x63;o&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#x43;&#x6f;&#109;mu&#x6e;&#x69;&#99;&#97;t&#x69;&#x6f;&#110;&#115;&#64;&#x54;&#x65;&#x76;&#111;ge&#x6e;&#x2e;&#99;&#111;m<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>The primary study endpoints were related to safety. No dose-limiting toxicities or significant adverse events related to TVGN 489, including Cytokine Release Syndrome, were observed in any patient at any dose level. Secondary endpoints measuring the reduction of viral load and the presence of cellular and humoral anti-COVID-19 responses after treatment were met. Fifty percent &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/tevogen-bio-announces-positive-proof-of-concept-clinical-trial-results-of-its-off-the-shelf-allogeneic-cytotoxic-cd8-t-cell-therapy-for-treatment-of-acute-high-risk-covid-patients-first-clinical-pr\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-53190","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Tevogen Bio Announces Positive Proof-of-Concept Clinical Trial Results of Its Off-The-Shelf, Allogeneic Cytotoxic CD8+ T Cell Therapy for Treatment of Acute High-Risk COVID Patients, First Clinical Product of Company\u2019s Precision Cell Therapy Platform - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/tevogen-bio-announces-positive-proof-of-concept-clinical-trial-results-of-its-off-the-shelf-allogeneic-cytotoxic-cd8-t-cell-therapy-for-treatment-of-acute-high-risk-covid-patients-first-clinical-pr\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tevogen Bio Announces Positive Proof-of-Concept Clinical Trial Results of Its Off-The-Shelf, Allogeneic Cytotoxic CD8+ T Cell Therapy for Treatment of Acute High-Risk COVID Patients, First Clinical Product of Company\u2019s Precision Cell Therapy Platform - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"The primary study endpoints were related to safety. No dose-limiting toxicities or significant adverse events related to TVGN 489, including Cytokine Release Syndrome, were observed in any patient at any dose level. Secondary endpoints measuring the reduction of viral load and the presence of cellular and humoral anti-COVID-19 responses after treatment were met. Fifty percent ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/tevogen-bio-announces-positive-proof-of-concept-clinical-trial-results-of-its-off-the-shelf-allogeneic-cytotoxic-cd8-t-cell-therapy-for-treatment-of-acute-high-risk-covid-patients-first-clinical-pr\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-23T16:02:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230123005565\/en\/1073275\/21\/Tevogen_Logo_800px.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tevogen-bio-announces-positive-proof-of-concept-clinical-trial-results-of-its-off-the-shelf-allogeneic-cytotoxic-cd8-t-cell-therapy-for-treatment-of-acute-high-risk-covid-patients-first-clinical-pr\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tevogen-bio-announces-positive-proof-of-concept-clinical-trial-results-of-its-off-the-shelf-allogeneic-cytotoxic-cd8-t-cell-therapy-for-treatment-of-acute-high-risk-covid-patients-first-clinical-pr\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Tevogen Bio Announces Positive Proof-of-Concept Clinical Trial Results of Its Off-The-Shelf, Allogeneic Cytotoxic CD8+ T Cell Therapy for Treatment of Acute High-Risk COVID Patients, First Clinical Product of Company\u2019s Precision Cell Therapy Platform\",\"datePublished\":\"2023-01-23T16:02:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tevogen-bio-announces-positive-proof-of-concept-clinical-trial-results-of-its-off-the-shelf-allogeneic-cytotoxic-cd8-t-cell-therapy-for-treatment-of-acute-high-risk-covid-patients-first-clinical-pr\\\/\"},\"wordCount\":1379,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tevogen-bio-announces-positive-proof-of-concept-clinical-trial-results-of-its-off-the-shelf-allogeneic-cytotoxic-cd8-t-cell-therapy-for-treatment-of-acute-high-risk-covid-patients-first-clinical-pr\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230123005565\\\/en\\\/1073275\\\/21\\\/Tevogen_Logo_800px.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tevogen-bio-announces-positive-proof-of-concept-clinical-trial-results-of-its-off-the-shelf-allogeneic-cytotoxic-cd8-t-cell-therapy-for-treatment-of-acute-high-risk-covid-patients-first-clinical-pr\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tevogen-bio-announces-positive-proof-of-concept-clinical-trial-results-of-its-off-the-shelf-allogeneic-cytotoxic-cd8-t-cell-therapy-for-treatment-of-acute-high-risk-covid-patients-first-clinical-pr\\\/\",\"name\":\"Tevogen Bio Announces Positive Proof-of-Concept Clinical Trial Results of Its Off-The-Shelf, Allogeneic Cytotoxic CD8+ T Cell Therapy for Treatment of Acute High-Risk COVID Patients, First Clinical Product of Company\u2019s Precision Cell Therapy Platform - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tevogen-bio-announces-positive-proof-of-concept-clinical-trial-results-of-its-off-the-shelf-allogeneic-cytotoxic-cd8-t-cell-therapy-for-treatment-of-acute-high-risk-covid-patients-first-clinical-pr\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tevogen-bio-announces-positive-proof-of-concept-clinical-trial-results-of-its-off-the-shelf-allogeneic-cytotoxic-cd8-t-cell-therapy-for-treatment-of-acute-high-risk-covid-patients-first-clinical-pr\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230123005565\\\/en\\\/1073275\\\/21\\\/Tevogen_Logo_800px.jpg\",\"datePublished\":\"2023-01-23T16:02:46+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tevogen-bio-announces-positive-proof-of-concept-clinical-trial-results-of-its-off-the-shelf-allogeneic-cytotoxic-cd8-t-cell-therapy-for-treatment-of-acute-high-risk-covid-patients-first-clinical-pr\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tevogen-bio-announces-positive-proof-of-concept-clinical-trial-results-of-its-off-the-shelf-allogeneic-cytotoxic-cd8-t-cell-therapy-for-treatment-of-acute-high-risk-covid-patients-first-clinical-pr\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tevogen-bio-announces-positive-proof-of-concept-clinical-trial-results-of-its-off-the-shelf-allogeneic-cytotoxic-cd8-t-cell-therapy-for-treatment-of-acute-high-risk-covid-patients-first-clinical-pr\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230123005565\\\/en\\\/1073275\\\/21\\\/Tevogen_Logo_800px.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230123005565\\\/en\\\/1073275\\\/21\\\/Tevogen_Logo_800px.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tevogen-bio-announces-positive-proof-of-concept-clinical-trial-results-of-its-off-the-shelf-allogeneic-cytotoxic-cd8-t-cell-therapy-for-treatment-of-acute-high-risk-covid-patients-first-clinical-pr\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tevogen Bio Announces Positive Proof-of-Concept Clinical Trial Results of Its Off-The-Shelf, Allogeneic Cytotoxic CD8+ T Cell Therapy for Treatment of Acute High-Risk COVID Patients, First Clinical Product of Company\u2019s Precision Cell Therapy Platform\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Tevogen Bio Announces Positive Proof-of-Concept Clinical Trial Results of Its Off-The-Shelf, Allogeneic Cytotoxic CD8+ T Cell Therapy for Treatment of Acute High-Risk COVID Patients, First Clinical Product of Company\u2019s Precision Cell Therapy Platform - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/tevogen-bio-announces-positive-proof-of-concept-clinical-trial-results-of-its-off-the-shelf-allogeneic-cytotoxic-cd8-t-cell-therapy-for-treatment-of-acute-high-risk-covid-patients-first-clinical-pr\/","og_locale":"en_US","og_type":"article","og_title":"Tevogen Bio Announces Positive Proof-of-Concept Clinical Trial Results of Its Off-The-Shelf, Allogeneic Cytotoxic CD8+ T Cell Therapy for Treatment of Acute High-Risk COVID Patients, First Clinical Product of Company\u2019s Precision Cell Therapy Platform - Pharma Trend","og_description":"The primary study endpoints were related to safety. No dose-limiting toxicities or significant adverse events related to TVGN 489, including Cytokine Release Syndrome, were observed in any patient at any dose level. Secondary endpoints measuring the reduction of viral load and the presence of cellular and humoral anti-COVID-19 responses after treatment were met. Fifty percent ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/tevogen-bio-announces-positive-proof-of-concept-clinical-trial-results-of-its-off-the-shelf-allogeneic-cytotoxic-cd8-t-cell-therapy-for-treatment-of-acute-high-risk-covid-patients-first-clinical-pr\/","og_site_name":"Pharma Trend","article_published_time":"2023-01-23T16:02:46+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230123005565\/en\/1073275\/21\/Tevogen_Logo_800px.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/tevogen-bio-announces-positive-proof-of-concept-clinical-trial-results-of-its-off-the-shelf-allogeneic-cytotoxic-cd8-t-cell-therapy-for-treatment-of-acute-high-risk-covid-patients-first-clinical-pr\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/tevogen-bio-announces-positive-proof-of-concept-clinical-trial-results-of-its-off-the-shelf-allogeneic-cytotoxic-cd8-t-cell-therapy-for-treatment-of-acute-high-risk-covid-patients-first-clinical-pr\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Tevogen Bio Announces Positive Proof-of-Concept Clinical Trial Results of Its Off-The-Shelf, Allogeneic Cytotoxic CD8+ T Cell Therapy for Treatment of Acute High-Risk COVID Patients, First Clinical Product of Company\u2019s Precision Cell Therapy Platform","datePublished":"2023-01-23T16:02:46+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/tevogen-bio-announces-positive-proof-of-concept-clinical-trial-results-of-its-off-the-shelf-allogeneic-cytotoxic-cd8-t-cell-therapy-for-treatment-of-acute-high-risk-covid-patients-first-clinical-pr\/"},"wordCount":1379,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/tevogen-bio-announces-positive-proof-of-concept-clinical-trial-results-of-its-off-the-shelf-allogeneic-cytotoxic-cd8-t-cell-therapy-for-treatment-of-acute-high-risk-covid-patients-first-clinical-pr\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230123005565\/en\/1073275\/21\/Tevogen_Logo_800px.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/tevogen-bio-announces-positive-proof-of-concept-clinical-trial-results-of-its-off-the-shelf-allogeneic-cytotoxic-cd8-t-cell-therapy-for-treatment-of-acute-high-risk-covid-patients-first-clinical-pr\/","url":"https:\/\/pharma-trend.com\/en\/tevogen-bio-announces-positive-proof-of-concept-clinical-trial-results-of-its-off-the-shelf-allogeneic-cytotoxic-cd8-t-cell-therapy-for-treatment-of-acute-high-risk-covid-patients-first-clinical-pr\/","name":"Tevogen Bio Announces Positive Proof-of-Concept Clinical Trial Results of Its Off-The-Shelf, Allogeneic Cytotoxic CD8+ T Cell Therapy for Treatment of Acute High-Risk COVID Patients, First Clinical Product of Company\u2019s Precision Cell Therapy Platform - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/tevogen-bio-announces-positive-proof-of-concept-clinical-trial-results-of-its-off-the-shelf-allogeneic-cytotoxic-cd8-t-cell-therapy-for-treatment-of-acute-high-risk-covid-patients-first-clinical-pr\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/tevogen-bio-announces-positive-proof-of-concept-clinical-trial-results-of-its-off-the-shelf-allogeneic-cytotoxic-cd8-t-cell-therapy-for-treatment-of-acute-high-risk-covid-patients-first-clinical-pr\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230123005565\/en\/1073275\/21\/Tevogen_Logo_800px.jpg","datePublished":"2023-01-23T16:02:46+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/tevogen-bio-announces-positive-proof-of-concept-clinical-trial-results-of-its-off-the-shelf-allogeneic-cytotoxic-cd8-t-cell-therapy-for-treatment-of-acute-high-risk-covid-patients-first-clinical-pr\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/tevogen-bio-announces-positive-proof-of-concept-clinical-trial-results-of-its-off-the-shelf-allogeneic-cytotoxic-cd8-t-cell-therapy-for-treatment-of-acute-high-risk-covid-patients-first-clinical-pr\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/tevogen-bio-announces-positive-proof-of-concept-clinical-trial-results-of-its-off-the-shelf-allogeneic-cytotoxic-cd8-t-cell-therapy-for-treatment-of-acute-high-risk-covid-patients-first-clinical-pr\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230123005565\/en\/1073275\/21\/Tevogen_Logo_800px.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230123005565\/en\/1073275\/21\/Tevogen_Logo_800px.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/tevogen-bio-announces-positive-proof-of-concept-clinical-trial-results-of-its-off-the-shelf-allogeneic-cytotoxic-cd8-t-cell-therapy-for-treatment-of-acute-high-risk-covid-patients-first-clinical-pr\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Tevogen Bio Announces Positive Proof-of-Concept Clinical Trial Results of Its Off-The-Shelf, Allogeneic Cytotoxic CD8+ T Cell Therapy for Treatment of Acute High-Risk COVID Patients, First Clinical Product of Company\u2019s Precision Cell Therapy Platform"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53190","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=53190"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53190\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=53190"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=53190"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=53190"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}